Information Provided By: 
Fly News Breaks for February 5, 2016
VRTX
Feb 5, 2016 | 10:21 EDT
Piper Jaffray analyst Edward Tenthoff said the "dramatic" selloff in Vertex after the FDA said that it cannot currently approve a label expansion for Kalydeco in children with residual function mutations more than accounts for the missed revenue opportunity. The analyst keeps on Overweight rating on Vertex shares, citing the upcoming launch of Orkambi in the U.S. and expectations for the company to return to sustainable profitability. Vertex shares are down 2.5% in early trading to $89.47.
News For VRTX From the Last 2 Days
There are no results for your query VRTX
